Product performance engineering reviewed the incident information; however, there was no reported device malfunction and the product was not returned.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.The reported patient effect of pain and thrombosis are listed in electronic instructions for use, peripheral stent system rx herculink elite, ce as known patient effects of coronary stenting procedures a conclusive cause for the reported patient effects and the relationship to the product, if any, cannot be determined.Additionally, treatment appears to be related to circumstances of the procedure.There is no indication of a product quality issue with respect to the design, manufacture, or labeling of the device.The other herculink stent referenced is filed under separate medwatch report number.
|
It was reported that the procedure was to treat stenosis in the left renal artery and in-stent restenosis at the right renal artery.A 6.0x12mm herculink elite stent was successfully implanted at the left artery and another same size herculink was implanted at the right artery.Later that afternoon, the patient experienced abdominal pain with nausea and vomiting.A cat scan was performed and noted thrombosis in both renal arteries.Heparin was administered.The next morning ultrasound was performed.The right renal artery was fully opened; however, the status of the left renal artery could not be interpreted.Additionally, a hematoma was noted at the left femoral puncture site with active bleeding.The patient was taken to surgery where the artery was sutured, and the patient received a blood transfusion.The patient recovered and was walking in the unit.No additional information was provided.
|